|1.47||+0.0050||+0.34%||Vol 2.61M||1Y Perf -47.09%|
|Jul 7th, 2020 11:52 DELAYED|
|-1.46 -100.00%||- -%|
|Target Price||8.38||Analyst Rating||Strong Buy 1.50|
|Potential %||475.95||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/78/93||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||100/-42/49||Growth Ranking||★★ 44.53|
|Insiders Shares Cnt. % 3/6/12 mo.||100/-18/46||Income Ranking||— -|
|Market Cap||398.02M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||17.65||Earnings Date||4th Aug 2020|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2020|
|Estimated EPS Next Report||-0.15|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||4.19M|
|Avg. Monthly Volume||4.82M|
|Avg. Quarterly Volume||5.57M|
TherapeuticsMD Inc. (NASDAQ: TXMD) stock closed at 1.46 per share at the end of the most recent trading day (a 5.04% change compared to the prior day closing price) with a volume of 4.46M shares and market capitalization of 398.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 241 people. TherapeuticsMD Inc. CEO is Robert G. Finizio.
The one-year performance of TherapeuticsMD Inc. stock is -47.09%, while year-to-date (YTD) performance is -39.67%. TXMD stock has a five-year performance of -82.15%. Its 52-week range is between 0.853 and 4.32, which gives TXMD stock a 52-week price range ratio of 17.65%
TherapeuticsMD Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 46.65, a price-to-sale (PS) ratio of 7.65, a price to cashflow ratio of 0.40, a PEG ratio of 2.32, a ROA of -85.89%, a ROC of -99.14% and a ROE of -2 499.18%. The company’s profit margin is -%, its EBITDA margin is -292.70%, and its revenue ttm is $51.87 Million , which makes it $0.19 revenue per share.
Of the last four earnings reports from TherapeuticsMD Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. TherapeuticsMD Inc.’s next earnings report date is 04th Aug 2020.
The consensus rating of Wall Street analysts for TherapeuticsMD Inc. is Strong Buy (1.5), with a target price of $8.38, which is +475.95% compared to the current price. The earnings rating for TherapeuticsMD Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
TherapeuticsMD Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
TherapeuticsMD Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 26.08, ATR14 : 0.12, CCI20 : 124.41, Chaikin Money Flow : -0.08, MACD : 0.03, Money Flow Index : 47.56, ROC : 21.67, RSI : 61.28, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 60.46, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of TherapeuticsMD Inc. in the last 12-months were: Angus Charles Russell (Buy at a value of $126 600), Brian Bernick (Buy at a value of $127 700), Cooper C. Collins (Buy at a value of $107 300), Jane F. Barlow (Buy at a value of $9 998), John C.K. Milligan (Buy at a value of $274 700), John Milligan (Buy at a value of $274 700), Mitchell L. Krassan (Option Excercise at a value of $59 387), Mitchell L. Krassan (Sold 300 000 shares of value $676 920 ), Paul M. Bisaro (Buy at a value of $57 000), Robert G. Finizio (Buy at a value of $998 998), Tommy G. Thompson (Buy at a value of $25 031)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.